{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Untreated+Metastatic+Pancreatic+Ductal+Adenocarcinoma", "query": { "condition": "Untreated Metastatic Pancreatic Ductal Adenocarcinoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 21, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Untreated+Metastatic+Pancreatic+Ductal+Adenocarcinoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-10T12:26:56.687Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01893801", "title": "Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Stage IV Pancreatic Cancer" ], "interventions": [ { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pancreatic Cancer Research Team", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2013-05", "completion_date": "2017-10-01", "has_results": true, "last_update_posted_date": "2019-05-29", "last_synced_at": "2026-06-10T12:26:56.687Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • New Brunswick, New Jersey • Bethlehem, Pennsylvania", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Bethlehem", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01893801" }, { "nct_id": "NCT02575508", "title": "Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colon Adenocarcinoma", "Metastatic Pancreatic Adenocarcinoma", "Pancreatic Adenocarcinoma", "Pancreatic Ductal Adenocarcinoma", "Rectal Adenocarcinoma", "Stage III Pancreatic Cancer", "Stage IIIA Colon Cancer", "Stage IIIA Rectal Cancer", "Stage IIIB Colon Cancer", "Stage IIIB Rectal Cancer", "Stage IIIC Colon Cancer", "Stage IIIC Rectal Cancer", "Stage IV Pancreatic Cancer", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer" ], "interventions": [ { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "pan FGFR Kinase Inhibitor BGJ398", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2016-05-20", "last_synced_at": "2026-06-10T12:26:56.687Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02575508" }, { "nct_id": "NCT04753879", "title": "Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2021-09-29", "completion_date": "2026-07-01", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-06-10T12:26:56.687Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04753879" }, { "nct_id": "NCT07522073", "title": "A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "INCB161734", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Investigator's choice of chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 588, "start_date": "2026-04-09", "completion_date": "2029-03-19", "has_results": false, "last_update_posted_date": "2026-06-09", "last_synced_at": "2026-06-10T12:26:56.687Z", "location_count": 68, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 53 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07522073" }, { "nct_id": "NCT03415854", "title": "Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Pancreatic Ductal Adenocarcinoma", "Pancreatic Adenocarcinoma", "Pancreas Metastases", "Adenocarcinoma" ], "interventions": [ { "name": "Paricalcitol (Zemplar)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HonorHealth Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2018-01-31", "completion_date": "2023-12-11", "has_results": true, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-06-10T12:26:56.687Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03415854" }, { "nct_id": "NCT07076121", "title": "A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Navlimetostat", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 470, "start_date": "2025-10-23", "completion_date": "2029-05-03", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-06-10T12:26:56.687Z", "location_count": 48, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Springdale, Arkansas + 38 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07076121" }, { "nct_id": "NCT06648434", "title": "MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Pancreatic Ductal Adenocarcinoma", "Pancreatic Cancer", "Cancer of the Pancreas" ], "interventions": [ { "name": "Zunsemetinib", "type": "DRUG" }, { "name": "mFOLFIRINOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2025-06-13", "completion_date": "2030-05-31", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-06-10T12:26:56.687Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06648434" }, { "nct_id": "NCT02101021", "title": "Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Momelotinib", "type": "DRUG" }, { "name": "Placebo to match momelotinib", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sierra Oncology LLC - a GSK company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2014-06-02", "completion_date": "2017-04-10", "has_results": true, "last_update_posted_date": "2023-06-29", "last_synced_at": "2026-06-10T12:26:56.687Z", "location_count": 4, "location_summary": "Los Angeles, California • Goshen, Indiana • Boston, Massachusetts + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Goshen", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Tacoma", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02101021" }, { "nct_id": "NCT02109445", "title": "Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Cancer Pancreas" ], "interventions": [ { "name": "PF-03084014", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2014-09-03", "completion_date": "2014-11-06", "has_results": true, "last_update_posted_date": "2019-01-10", "last_synced_at": "2026-06-10T12:26:56.687Z", "location_count": 5, "location_summary": "Aurora, Colorado • Rochester, New York", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Rochester", "state": "New York" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02109445" }, { "nct_id": "NCT03915444", "title": "Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "NabCG (nab-Paclitaxel + Cisplatin + Gemcitabine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HonorHealth Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "105 Years", "sex": "ALL", "summary": "18 Years to 105 Years" }, "enrollment_count": 42, "start_date": "2019-07-15", "completion_date": "2023-01-23", "has_results": true, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-06-10T12:26:56.687Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Miami, Florida • New Orleans, Louisiana + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Miami", "state": "Florida" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03915444" } ] }